Navigation Links
U.S. and European Rheumatologists Agree That a Therapy's Induction of Remission is One of the Attributes That Most Influences Their Prescribing Decisions in Rheumatoid Arthritis
Date:6/19/2013

BURLINGTON, Mass., June 19, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of rheumatoid arthritis, the majority of surveyed U.S. and European rheumatologists cite a therapy's induction of remission as one of the attributes that most influences their prescribing decisions. Over 60 percent and 70 percent of U.S. and European rheumatologists, respectively, rank the percentage of patients achieving remission at six months as one of the top three most persuasive end points when prescribing a new drug for rheumatoid arthritis.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The DecisionBase rheumatoid arthritis report entitled In a Market Filled with Efficacious Drugs, Which Efficacy and Safety Achievements Have the Greatest Influence with Physicians and Payers? finds that surveyed rheumatologists also indicate there is a moderate unmet need for therapies with a greater ability to induce remission. Therapies with a greater ability to induce remission at six months have a meaningful opportunity for differentiation.

The report also finds that, according to interviewed thought leaders and clinical data, tocilizumab (Roche/Chugai's Actemra/RoActemra) has a minor advantage over AbbVie/Eisai's Humira for its ability to effect remission at six months, whereas Pfizer/Takeda's Xeljanz is at a disadvantage to Humira on this end point. 

"However, in spite of thought-leader opinion and clinical trial data support for IV tocilizumab's excellent efficacy, the drug is predominantly used as a later-line biologic because of payer restrictions, concerns about monitoring and managing its side effects, its more-limited postmarketing experience and its need for IV infusion," said Decision Resources Senior Director Madhuri Borde, Ph.D.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
2. CTI Announces Data Presentations at the 18th Congress of the European Hematology Association
3. Hospira Data on European Biosimilar Epoetin, Retacrit, Affirm Treatment Response, Tolerability in Management of Anemia Secondary to Chemotherapy
4. Oramed Selected to Present at the 81st European Atherosclerosis Society Congress in Lyon, France, June 2-5, 2013
5. Cardica Completes Enrollment In European Clinical Trial For Surgical Cutting And Stapling Device
6. Life Care Medical Devices Ltd Announces Addition Of Dublin, Ireland Based European Subsidiary
7. The European Alcohol Addiction Market is Poised For a Treatment Paradigm Shift With the Launch of BioTie/Lundbecks Selincro
8. Demand for Hybrid Solutions to Spur European Interventional Radiology and Cardiology Markets, finds Frost & Sullivan
9. Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
10. Combination Drugs are the Future of the European Hepatitis B and C Therapeutics Markets, Says Frost & Sullivan
11. Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2017)... , June 19, 2017  Researchers from DRUGSCAN ® ... they will host a live, complimentary webinar titled, "Untangling ... benchtop to the real world" on Wednesday June 28, ... This webinar will feature interviews with recreational ... into the manipulation techniques abusers use to prepare opioid ...
(Date:6/14/2017)... , June 14, 2017  ivWatch LLC, a ... effectiveness of intravenous (IV) therapy, is pleased to announce ... category of Nonsurgical Hospital Supplies and Equipment at the ... program for the medtech industry. The award was presented ... Jacob K. Javits Center in New York ...
(Date:6/13/2017)... , June 13, 2017 Zimmer Biomet Holdings, Inc. ... today announced that the U.S. Food and Drug Administration (FDA) ... 3, 2015 relating to its Zhejiang, China ... "The successful clearance of the Warning Letter ... manufacturing facility is a measure of the progress we have ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island Quality ... Management Alerts and Dashboards, an innovative new service enabling healthcare providers to proactively ... Management Alerts and Dashboards provide near real-time data about patients admitted to and/or ...
(Date:6/23/2017)... ... ... By scoring 100% for fiscal management and accountability, the Arthritis National Research ... Charity Navigator, validating ANRF's work as a top charity in America. , This achievement ... earns ANRF a spot on their “ 10 Charities Worth Watching ” list as ...
(Date:6/23/2017)... ... ... Studies show evidence that carotenoids and antioxidants derived either from the diet or from ... how often do ophthalmologists and optometrists in Sweden recommend the use of nutritional supplements, ... symptoms of AMD? A study published recently in Dove Medical Press journal, ...
(Date:6/23/2017)... ... June 23, 2017 , ... Dr. Ran Y. ... has recently begun offering three new minimally invasive procedures to patients who want ... reducing downtime, Dr. Rubinstein is excited to bring microneedling, microneedling facials, and platelet ...
(Date:6/23/2017)... ... 2017 , ... Everybody has their own personal preference when it comes to ... some people don't like it at all. FindaTopDoc took a look at what makes ... can give readers a taste of their deepest, darkest fantasies and has the ability ...
Breaking Medicine News(10 mins):